Last reviewed · How we verify

NCT02972918: OPL

Preoperative Optimization Levosimendan in Heart Failure Patients Undergoing Hip Fracture

Completed Last updated 3 February 2020
What this trial tests

trial testing Levosimendan in Ventricular Dysfunction, Left in 19 participants. Completed in 1 April 2019.

Timeline
1 May 2014
Primary endpoint
1 September 2018
1 April 2019

Quick facts

Lead sponsorHospital Universitario de Canarias
StatusCompleted
Study typeOBSERVATIONAL
Enrollment19
Start date1 May 2014
Primary completion1 September 2018
Estimated completion1 April 2019
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Hospital Universitario de Canarias

Who can join

Adults 18 to 100, any sex, with Ventricular Dysfunction, Left or Hip Fracture. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to evaluate whether preoperative optimization with levosimendan in heart failure patients undergoing hip fracture surgery improves haemodynamic and tissue perfusion parameters.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Levosimendan

Trials testing the same drug.

Other recruiting trials for Ventricular Dysfunction, Left

Currently open trials in the same condition.

Other Hospital Universitario de Canarias trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02972918.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing